Jiong Lyu1, Hao Song2, Zhen Tian3, Yuwen Miao4, Guoxin Ren2, Wei Guo5. 1. The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. 2. Department of Oral and Maxillofacial-Head and Neck Oncology, Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. 3. Department of Oral Pathology, Ninth people's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. 4. Department of Head and Neck Surgery, Sir Run Run Shao Hospital, Zhejiang University School of Medicine, Hangzhou, China. 5. Department of Oral and Maxillofacial-Head and Neck Oncology, Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. Electronic address: Guoweicn@yahoo.com.
Abstract
OBJECTIVE: Molecular alterations in downstream effectors of epidermal growth factor receptor may confer resistance to epidermal growth factor receptor inhibitors. Our aim is to investigate whether PTEN/pAKT expression predicts response to cetuximab-based chemotherapy in oral squamous cell carcinoma. STUDY DESIGN: We analyzed a cohort of 50 patients with oral squamous cell carcinoma treated with cetuximab-based induction chemotherapy. PTEN expression and pAKT expression were assessed by immunohistochemistry and their correlation with treatment outcome was analyzed. RESULTS: Of the study patients, 18.4% had low PTEN expression, and 38.8% had high pAKT expression. Lower pAKT expression were associated with pathologic remission (P = .034) and better disease-free survival (P = .031). CONCLUSION: Our study demonstrates that pAKT expression is a predictive biomarker of cetuximab-based induction chemotherapy in OSCC.
OBJECTIVE: Molecular alterations in downstream effectors of epidermal growth factor receptor may confer resistance to epidermal growth factor receptor inhibitors. Our aim is to investigate whether PTEN/pAKT expression predicts response to cetuximab-based chemotherapy in oral squamous cell carcinoma. STUDY DESIGN: We analyzed a cohort of 50 patients with oral squamous cell carcinoma treated with cetuximab-based induction chemotherapy. PTEN expression and pAKT expression were assessed by immunohistochemistry and their correlation with treatment outcome was analyzed. RESULTS: Of the study patients, 18.4% had low PTEN expression, and 38.8% had high pAKT expression. Lower pAKT expression were associated with pathologic remission (P = .034) and better disease-free survival (P = .031). CONCLUSION: Our study demonstrates that pAKT expression is a predictive biomarker of cetuximab-based induction chemotherapy in OSCC.
Authors: Anna Starzyńska; Aleksandra Sejda; Paulina Adamska; Giulia Marvaso; Monika Sakowicz-Burkiewicz; Łukasz Adamski; Barbara A Jereczek-Fossa Journal: Arch Med Sci Date: 2020-11-13 Impact factor: 3.318